Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-x24gv Total loading time: 0 Render date: 2024-05-01T08:48:29.429Z Has data issue: false hasContentIssue false

Chapter 8 - Pharmacology of neurokinin antagonists and novel antiemetics

Published online by Cambridge University Press:  05 March 2016

By
Linda M.L. Lai ,
William K.K. Wu  and
Matthew T.V. Chan
Edited by
Tong Joo Gan  and
Ashraf S. Habib
Foreword by
Henrik Kehlet
Tong Joo Gan
Affiliation:
Duke University Medical Center, Durham
Ashraf S. Habib
Affiliation:
Duke University Medical Center, Durham
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Postoperative Nausea and Vomiting
A Practical Guide
 , pp. 74 - 89
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

von Euler, US, Gaddum, JH. An unidentified depressor substance in certain tissue extracts. J Physiol 1931; 72: 74–87.CrossRefGoogle Scholar
Newton, BW, Maley, B, Traurig, H. The distribution of substance P, enkephalin, and serotonin immunoreactivities in the area postrema of the rat and cat. J Comp Neurol 1985; 234: 87–104.CrossRefGoogle ScholarPubMed
Baude, A, Lanoir, J, Vernier, P, Puizillout, JJ. Substance P-immunoreactivity in the dorsal medial region of the medulla in the cat: effects of nodosectomy. J Chem Neuroanat 1989; 2: 67–81.Google ScholarPubMed
Armstrong, DM, Pickel, VM, Reis, DJ. Electron microscopic immunocytochemical localization of substance P in the area postrema of rat. Brain Res 1982; 243: 141–6.CrossRefGoogle ScholarPubMed
Carpenter, DO, Briggs, DB, Strominger, N. Peptide-induced emesis in dogs. Behav Brain Res 1984; 11: 277–81.CrossRefGoogle ScholarPubMed
Andrews, PL, Bhandari, P. Resinferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret. Neuropharmacology 1993; 32: 799–806.CrossRefGoogle ScholarPubMed
Tregear, GW, Niall, HD, Potts, JT Jr, et al. Synthesis of substance P. Nat New Biol 1971; 232: 87–9.CrossRefGoogle ScholarPubMed
Chang, MM, Leeman, SE, Niall, HD. Amino-acid sequence of substance P. Nat New Biol 1971; 232: 86–7.CrossRefGoogle ScholarPubMed
Steinhoff, MS, von Mentzer, B, Geppetti, P, et al. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev 2014; 94: 265–301.CrossRefGoogle ScholarPubMed
Almeida, TA, Rojo, J, Nieto, PM, et al. Tachykinins and tachykinin receptors: structure and activity relationships. Curr Med Chem 2004; 11: 2045–81.CrossRefGoogle ScholarPubMed
Quartara, L, Maggi, CA. The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles. Neuropeptides 1998; 32: 1–49.CrossRefGoogle ScholarPubMed
Quartara, L, Maggi, CA. The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation. Neuropeptides 1997; 31: 537–63.CrossRefGoogle ScholarPubMed
Shimizu, Y, Matsuyama, H, Shiina, T, et al. Tachykinins and their functions in the gastrointestinal tract. Cell Mol Life Sci 2008; 65: 295–311.CrossRefGoogle ScholarPubMed
Chen, P, Douglas, SD, Meshki, J, et al. Neurokinin 1 receptor mediates membrane blebbing and sheer stress-induced microparticle formation in HEK293 cells. PLoS ONE 2012; 7: e45322.CrossRefGoogle ScholarPubMed
Koon, HW, Zhao, D, Na, X, et al. Metalloproteinases and transforming growth factor-alpha mediate substance P-induced mitogen-activated protein kinase activation and proliferation in human colonocytes. J Biol Chem 2004; 279: 45519–27.CrossRefGoogle ScholarPubMed
Engberg, G, Svensson, TH, Rosell, S, et al. A synthetic peptide as an antagonist of substance P. Nature 1981; 293: 222–3.CrossRefGoogle ScholarPubMed
Lee, CM, Campbell, NJ, Williams, BJ, et al. Multiple tachykinin binding-sites in peripheral-tissues and in brain. Eur J Pharmacol 1986; 130: 209–217.CrossRefGoogle ScholarPubMed
Rojas, C, Raje, M, Tsukamoto, T, et al. Molecular mechanisms of 5-HT3 and NK1 receptor antagonists in prevention of emesis. Eur J Pharmacol 2014; 722: 26–37.CrossRefGoogle ScholarPubMed
Huang, SC, Korlipara, VL. Neurokinin-1 receptor antagonists: a comprehensive patent survey. Expert Opin Ther Pat 2010; 20: 1019–45.CrossRefGoogle ScholarPubMed
Snider, RM, Constantine, JW, Lowe, JA, et al. A potent nonpeptide antagonist of the substance P (NK1) receptor. Science 1991; 251: 435–7.CrossRefGoogle ScholarPubMed
Desai, MC, Lefkowitz, SL, Thadeio, PF, et al. Discovery of a potent substance P antagonist: recognition of the key molecular determinant. J Med Chem 1992; 35: 4911–3.CrossRefGoogle ScholarPubMed
Schmidt, AW, McLean, S, Heym, J. The substance P receptor antagonist CP-96,345 interacts with Ca2+ channels. Eur J Pharmacol 1992; 219: 491–2.CrossRefGoogle ScholarPubMed
Hargreaves, R, Ferreira, JC, Hughes, D, et al. Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann N Y Acad Sci 2011; 1222: 40–8.CrossRefGoogle ScholarPubMed
Hale, JJ, Mills, SG, MacCoss, M, et al. 2(S)-((3,5-Bis(trifluoromethyl)benzyl)oxy)-3(S)-phenyl-4-((3-oxo-1,2,4-triazol- 5-yl)methyl)morpholine (1): A potent, orally active, morpholine-based human neurokinin-1 receptor antagonist. J Med Chem 1996; 39: 1760–2.CrossRefGoogle Scholar
Hale, JJ, Mills, SG, MacCoss, M, et al. Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs. J Med Chem 2000; 43: 1234–41.CrossRefGoogle ScholarPubMed
Di Fabio, R, Alvaro, G, Griffante, C, et al. Discovery and biological characterization of (2R,4S)-1′-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4′-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clinical candidate. J Med Chem 2011; 54: 1071–9.CrossRefGoogle Scholar
Rizzi, A, Campi, B, Camarda, V, et al. In vitro and in vivo pharmacological characterization of the novel NK1 receptor selective antagonist Netupitant. Peptides 2012; 37: 86–97.CrossRefGoogle ScholarPubMed
Duffy, RA, Morgan, C, Naylor, R, et al. Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets. Pharmacol Biochem Behav 2012; 102: 95–100.CrossRefGoogle ScholarPubMed
Rupniak, NM, Hill, RG. Neurokinin antagonists. In Novel aspects of pain management: opioids and beyond. Sawynok, J, Cowan, A (eds). New York: Wiley-Liss, 1999; 135–55.Google Scholar
De Koninck, Y, Henry, JL. Substance P-mediated slow excitatory postsynaptic potential elicited in dorsal horn neurons in vivo by noxious stimulation. Proc Natl Acad Sci U S A 1991; 88: 11344–8.CrossRefGoogle ScholarPubMed
Rupniak, NM, Kramer, MS. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol Sci 1999; 20: 485–90.CrossRefGoogle ScholarPubMed
Watson, JW, Gonsalves, SF, Fossa, AA, et al. The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor. Br J Pharmacol 1995; 115: 84–94.CrossRefGoogle ScholarPubMed
Lewis, CA, El-Hashim, AZ, Gerspacher, M, et al. The airways pharmacology of DNK333, a potent, selective, non-peptide dual NK1/NK2 receptor antagonist. Drug Develop Res 2004; 63: 161–173.CrossRefGoogle Scholar
Zakko, S, Barton, G, Weber, E, et al. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2011; 33: 1311–21.CrossRefGoogle ScholarPubMed
Tough, IR, Lewis, CA, Fozard, J, et al. Dual and selective antagonism of neurokinin NK(1) and NK(2) receptor-mediated responses in human colon mucosa. Naunyn Schmiedebergs Arch Pharmacol 2003; 367: 104–8.CrossRefGoogle Scholar
Ohmura, T, Hayashi, T, Satoh, Y, et al. Involvement of substance P in scratching behaviour in an atopic dermatitis model. Eur J Pharmacol 2004; 491: 191–4.CrossRefGoogle Scholar
Doi, T, Kamo, I, Imai, S, et al. Effects of TAK-637, a tachykinin receptor antagonist, on the micturition reflex in guinea pigs. Eur J Pharmacol 2000; 395: 241–6.CrossRefGoogle ScholarPubMed
Shaikh, MB, Steinberg, A, Siegel, A. Evidence that substance P is utilized in medial amygdaloid facilitation of defensive rage behavior in the cat. Brain Res 1993; 625: 283–94.CrossRefGoogle ScholarPubMed
Kramer, MS, Cutler, N, Feighner, J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281: 1640–5.CrossRefGoogle ScholarPubMed
Lim, R, Morrill, JM, Prushik, SG, et al. An FDA approved neurokinin-1 receptor antagonist is effective in reducing intraabdominal adhesions when administered intraperitoneally, but not orally. J Gastrointest Surg 2008; 12: 1754–61.CrossRefGoogle Scholar
Hegde, A, Zhang, H, Moochhala, SM, et al. Neurokinin-1 receptor antagonist treatment protects mice against lung injury in polymicrobial sepsis. J Leukoc Biol 2007; 82: 678–85.CrossRefGoogle ScholarPubMed
Gillespie, E, Leeman, SE, Watts, LA, et al. Truncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer. Proc Natl Acad Sci U S A 2011; 108: 17420–5.CrossRefGoogle ScholarPubMed
Fahy, JV, Wong, HH, Geppetti, P, et al. Effect of an NK1 receptor antagonist (CP-99,994) on hypertonic saline-induced bronchoconstriction and cough in male asthmatic subjects. Am J Respir Crit Care Med 1995; 152: 879–84.CrossRefGoogle ScholarPubMed
Frenkl, TL, Zhu, H, Reiss, T, et al. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder. J Urol 2010; 184: 616–22.CrossRefGoogle ScholarPubMed
Hill, R. NK(1) (substance P) receptor antagonists – why are they not analgesic in humans? Trends Pharmacol Sci 2000; 21: 244–6.CrossRefGoogle Scholar
Dionne, RA, Max, MB, Gordon, SM, et al. The substance P receptor antagonist CP-99,994 reduces acute postoperative pain. Clin Pharmacol Ther 1998; 64: 562–8.CrossRefGoogle ScholarPubMed
Kakuta, N, Tsutsumi, YM, Horikawa, YT, et al. Neurokinin-1 receptor antagonism, aprepitant, effectively diminishes post-operative nausea and vomiting while increasing analgesic tolerance in laparoscopic gynecological procedures. J Med Invest 2011; 58: 246–51.CrossRefGoogle ScholarPubMed
Goldstein, DJ, Wang, O, Saper, JR, et al. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia 1997; 17: 785–90.CrossRefGoogle Scholar
Diener, HC; RPR100893 Study Group. RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia 2003; 23: 183–5.CrossRefGoogle Scholar
Goldstein, DJ, Wang, O, Gitter, BD, et al. Dose–response study of the analgesic effect of lanepitant in patients with painful diabetic neuropathy. Clin Neuropharmacol 2001; 24: 16–22.CrossRefGoogle ScholarPubMed
Sindrup, SH, Graf, A, Sfikas, N. The NK1-receptor antagonist TKA731 in painful diabetic neuropathy: a randomised, controlled trial. Eur J Pain 2006; 10: 567–71.CrossRefGoogle ScholarPubMed
Keller, M, Montgomery, S, Ball, W, et al. Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 2006; 59: 216–23.CrossRefGoogle ScholarPubMed
Urban, LA, Fox, AJ. NK(1) receptor antagonists – are they really without effect in the pain clinic. Trends Pharmacol Sci 2000; 21: 462–4.Google Scholar
Cocquyt, V, Van Belle, S, Reinhardt, RR, et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 2001; 37: 835–42.CrossRefGoogle ScholarPubMed
Fumoleau, P, Graham, E, Giovanni, M. Control of acute cisplatin-induced emesis and nausea with the NK1 receptor antagonist GR205171 in combination with ondansetron. Proc Annu Meet Am Soc Clin Oncol 1998; 17: 58a 255.Google Scholar
Kris, MG, Radford, JE, Pizzo, BA, et al. Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. J Natl Cancer Inst 1997; 89: 817–818.CrossRefGoogle ScholarPubMed
Hesketh, PJ, Gralla, RJ, Webb, RT, et al. Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol 1999; 17: 338–43.CrossRefGoogle ScholarPubMed
Warr, DG, Hesketh, PJ, Gralla, RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005; 23: 2822–30.CrossRefGoogle ScholarPubMed
Schmoll, HJ, Aapro, MS, Poli-Bigelli, S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006; 17: 1000–6.CrossRefGoogle ScholarPubMed
Poli-Bigelli, S, Rodrigues-Pereira, J, Carides, AD, et al. Aprepitant Protocol 054 Study Group. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97: 3090–8.CrossRefGoogle ScholarPubMed
Hesketh, PJ, Grunberg, SM, Gralla, RJ, et al. Aprepitant Protocol 052 Study Group. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112–9.CrossRefGoogle ScholarPubMed
Herrstedt, J, Muss, HB, Warr, DG, et al. Aprepitant Moderately Emetogenic Chemotherapy Study Group. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005; 104: 1548–55.CrossRefGoogle ScholarPubMed
de Wit, R, Herrstedt, J, Rapoport, B, et al. The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer 2004; 40: 403–10.CrossRefGoogle ScholarPubMed
Chawla, SP, Grunberg, SM, Gralla, RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003; 97: 2290–300.CrossRefGoogle ScholarPubMed
Grunberg, SM, Rolski, J, Strausz, J, et al. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 549–58.CrossRefGoogle ScholarPubMed
Herrstedt, J, Apornwirat, W, Shaharyar, A, et al. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol 2009; 27: 5363–9.CrossRefGoogle ScholarPubMed
Arpornwirat, W, Albert, I, Hansen, VL, et al. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy. Cancer 2009; 115: 5807–16.CrossRefGoogle ScholarPubMed
Gridelli, C, Haiderali, AM, Russo, MW, et al. Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy. Support Care Cancer 2010; 18: 1437–44.CrossRefGoogle ScholarPubMed
Hesketh, PJ, Rossi, G, Rizzi, G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 2014; 25: 1340–6.CrossRefGoogle ScholarPubMed
Aapro, M, Rugo, H, Rossi, G, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 2014; 25: 1328–33.CrossRefGoogle Scholar
Gralla, RJ, Bosnjak, SM, Hontsa, A, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 2014; 25: 1333–9.CrossRefGoogle Scholar
Roila, F, Herrstedt, J, Aapro, M, et al. ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010; 21 Suppl 5: v232–43.CrossRefGoogle ScholarPubMed
Diemunsch, P, Schoeffler, P, Bryssine, B, et al. Antiemetic activity of the NK1 receptor antagonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery. Br J Anaesth 1999; 82: 274–6.CrossRefGoogle ScholarPubMed
Gesztesi, Z, Scuderi, PE, White, PF, et al. Substance P (Neurokinin-1) antagonist prevents postoperative vomiting after abdominal hysterectomy procedures. Anesthesiology 2000; 93: 931–7.CrossRefGoogle ScholarPubMed
Gan, TJ, Apfel, CC, Kovac, A, et al. Aprepitant-PONV Study Group. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg 2007; 104: 1082–9.CrossRefGoogle ScholarPubMed
Diemunsch, P, Gan, TJ, Philip, BK, et al. Aprepitant-PONV Protocol International Study Group. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery. Br J Anaesth 2007; 99: 202–11.CrossRefGoogle ScholarPubMed
Diemunsch, P, Apfel, C, Gan, TJ, et al. Preventing postoperative nausea and vomiting: post hoc analysis of pooled data from two randomized active-controlled trials of aprepitant. Curr Med Res Opin 2007; 23: 2559–65.CrossRefGoogle ScholarPubMed
Habib, AS, Keifer, JC, Borel, CO, et al. A comparison of the combination of aprepitant and dexamethasone versus the combination of ondansetron and dexamethasone for the prevention of postoperative nausea and vomiting in patients undergoing craniotomy. Anesth Analg 2011; 112: 813–8.CrossRefGoogle ScholarPubMed
Tsutsumi, YM, Kakuta, N, Soga, T, et al. The effects of intravenous fosaprepitant and ondansetron for the prevention of postoperative nausea and vomiting in neurosurgery patients: a prospective, randomized, double-blinded study. Biomed Res Int 2014; 2014: 307025.CrossRefGoogle ScholarPubMed
Vallejo, MC, Phelps, AL, Ibinson, JW, et al. Aprepitant plus ondansetron compared with ondansetron alone in reducing postoperative nausea and vomiting in ambulatory patients undergoing plastic surgery. Plast Reconstr Surg 2012; 129: 519–26.CrossRefGoogle ScholarPubMed
Moon, HY, Baek, CW, Choi, GJ, et al. Palonosetron and aprepitant for the prevention of postoperative nausea and vomiting in patients indicated for laparoscopic gynaecologic surgery: a double-blind randomised trial. BMC Anesthesiol 2014; 14: 68.CrossRefGoogle ScholarPubMed
Lee, SJ, Lee, SM, Kim, SI, et al. The effect of aprepitant for the prevention of postoperative nausea and vomiting in patients undergoing gynecologic surgery with intravenous patient controlled analgesia using fentanyl: aprepitant plus ramosetron vs ramosetron alone. Korean J Anesthesiol 2012; 63: 221–6.CrossRefGoogle ScholarPubMed
Lim, CS, Ko, YK, Kim, YH, et al. Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting. Korean J Anesthesiol 2013; 64: 212–7.CrossRefGoogle ScholarPubMed
Sinha, AC, Singh, PM, Williams, NW, et al. Aprepitant’s prophylactic efficacy in decreasing postoperative nausea and vomiting in morbidly obese patients undergoing bariatric surgery. Obes Surg 2014; 24: 225–31.CrossRefGoogle ScholarPubMed
Altorjay, A, Melson, T, Chinachoit, T, et al. Casopitant and ondansetron for postoperative nausea and vomiting prevention in women at high risk for emesis: a phase 3 study. Arch Surg 2011; 146: 201–6.CrossRefGoogle ScholarPubMed
Singla, NK, Singla, SK, Chung, F, et al. Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients. Anesthesiology 2010; 113: 74–82.CrossRefGoogle ScholarPubMed
Gan, TJ, Gu, J, Singla, N, et al. Rolapitant Investigation Group. Rolapitant for the prevention of postoperative nausea and vomiting: a prospective, double-blinded, placebo-controlled randomized trial. Anesth Analg 2011; 112: 804–12.CrossRefGoogle ScholarPubMed
Reid, K, Palmer, JL, Wright, RJ, et al. Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man. Br J Clin Pharmacol 2000; 50: 61–4.CrossRefGoogle ScholarPubMed
Olver, I, Shelukar, S, Thompson, KC. Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant. Int J Nanomedicine 2007; 2: 13–8.CrossRefGoogle ScholarPubMed
Van Laere, K, De Hoon, J, Bormans, G, et al. Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. Clin Pharmacol Ther 2012; 92: 243–50.CrossRefGoogle ScholarPubMed
Curran, MP, Robinson, DM. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs 2009; 69: 1853–78.CrossRefGoogle ScholarPubMed
Majumdar, AK, McCrea, JB, Panebianco, DL, et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 2003; 74: 150–6.CrossRefGoogle ScholarPubMed
Shadle, CR, Lee, Y, Majumdar, AK, et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 2004; 44: 215–23.CrossRefGoogle ScholarPubMed
McCrea, JB, Majumdar, AK, Goldberg, MR, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003; 74: 17–24.CrossRefGoogle ScholarPubMed
Aapro, MS, Walko, CM. Aprepitant: drug–drug interactions in perspective. Ann Oncol 2010; 21: 2316–23.CrossRefGoogle Scholar
Depre, M, Van Hecken, A, Oeyen, M, et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 2005; 61: 341–6.Google ScholarPubMed
Lasseter, KC, Gambale, J, Jin, B, et al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 2007; 47: 834–40.CrossRefGoogle ScholarPubMed
Colon-Gonzalez, F, Kraft, WK. Pharmacokinetic evaluation of fosaprepitant dimeglumine. Expert Opin Drug Metab Toxicol 2010; 6: 1277–86.CrossRefGoogle ScholarPubMed
Ruhlmann, C, Herrstedt, J. Casopitant: a novel NK1-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting. Ther Clin Risk Manag 2009; 5: 375–84.Google ScholarPubMed
Zamuner, S, Rabiner, EA, Fernandes, SA, et al. A pharmacokinetic PET study of NK1 receptor occupancy. Eur J Nucl Med Mol Imaging 2012; 39: 226–35.CrossRefGoogle ScholarPubMed
Pellegatti, M, Bordini, E, Fizzotti, P, et al. Disposition and metabolism of radiolabeled casopitant in humans. Drug Metab Dispos 2009; 37: 1635–45.CrossRefGoogle ScholarPubMed
Lanzarotti, C, Rossi, G. Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone. Support Care Cancer 2013; 21: 2783–91.CrossRefGoogle ScholarPubMed
Munoz, M, Covenas, R. Safety of neurokinin-1 receptor antagonists. Expert Opin Drug Saf 2013; 12: 673–85.CrossRefGoogle ScholarPubMed
Coulouvrat, C, Dondey-Nouvel, L. Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol 1999; 14: 209–18.CrossRefGoogle ScholarPubMed
Leucht, S, Cipriani, A, Spineli, L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951–62.CrossRefGoogle ScholarPubMed
Kranke, P, Eberhart, L, Motsch, J, et al. I.V. APD421 (amisulpride) prevents postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled, multicentre trial. Br J Anaesth 2013; 111: 938–45.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×